genedrive plc (LON:GDR – Get Free Report) shares fell 7.1% during mid-day trading on Wednesday . The company traded as low as GBX 1.94 ($0.03) and last traded at GBX 1.94 ($0.03). 6,504,713 shares traded hands during mid-day trading, a decline of 55% from the average session volume of 14,579,251 shares. The stock had previously closed at GBX 2.09 ($0.03).
genedrive Stock Performance
The company has a market capitalization of £10.73 million, a P/E ratio of -52.25 and a beta of -0.04. The business has a 50-day moving average of GBX 3.06 and a 200-day moving average of GBX 3.24. The company has a debt-to-equity ratio of 8.57, a current ratio of 1.63 and a quick ratio of 5.52.
Insider Transactions at genedrive
In other genedrive news, insider Ian David Gilham bought 1,000,000 shares of the firm’s stock in a transaction dated Wednesday, August 14th. The stock was acquired at an average cost of GBX 3 ($0.04) per share, for a total transaction of £30,000 ($39,630.12). Corporate insiders own 14.78% of the company’s stock.
About genedrive
genedrive plc, a molecular diagnostics company, engages in developing and commercializing point of need diagnostics platform for infectious diseases, genotyping, pathogen detection, and other indications. The company provides Genedrive system, a rapid thermocycler and signal detection system and semi- automated system used forqualitative in vitro molecular diagnostic tests; and Genedrive CYP2C19 ID Kit, a point-of-care test for rapid CYP2C19 genotyping in time-critical emergency care settings.
Recommended Stories
- Five stocks we like better than genedrive
- Industrial Products Stocks Investing
- Galmed Pharmaceuticals Surges 400%: What’s Behind the Explosion?
- What is Forex and How Does it Work?
- Gold Hits New All-Time Highs: 3 Stocks to Ride the Surge
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Intel: Why It’s Time to Reconsider This Beaten-Down Chipmaker
Receive News & Ratings for genedrive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for genedrive and related companies with MarketBeat.com's FREE daily email newsletter.